Advancing Cyclic Immunofluorescence through Antibody Labeling
This event was held live on July 30th, 2026. Watch the recording.
This event was held live on July 30th, 2026.
Cyclic immunofluorescence (cyclic IF) is transforming spatial biology by enabling highly multiplexed protein detection while preserving tissue architecture.
Join Dr Oliver Hartmann, Senior Scientific Officer and Post-Doc, to discover how primary antibody labeling can advance cyclic IF workflows for the identification and characterization of novel lung cancer therapeutics.
Dr Hartmann explored key considerations for selecting and labeling antibodies, strategies to improve multiplex imaging performance, and how these approaches can be applied to accelerate biomarker discovery and therapeutic development in lung cancer research.
This webinar covered:
-
The principles of cyclic IF and its role in drug discovery
-
Novel antibody labeling techniques to support robust multiplex imaging
-
Considerations for minimizing cross-reactivity and maximizing signal quality across multiple staining cycles
-
Applications of cyclic IF for identifying and validating novel therapeutic targets in lung cancer
Dr Oliver Hartmann
Senior Scientific Officer and Post-Doc,
Experimental Immuno-Oncology Group at the Institute of Lung Health and Immunity, Helmholtz Munich.
Able™